COVID-19 Vaccine Development
- Biopharmaceutical Development on COVID:19
COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
Committee Members
Vladlen Slepak
University of Miami, United States
Yong Xiao Wang
Albany Medical College, United States
Axel H Schonthal
University of Southern California, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada PDDS 2026 Speakers
Madhav Bhatia
University of Otago, New Zealand
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Saad Tayyab
UCSI University, Malaysia
Lan Wang
Paretor LLC, United States
Ravi P Sahu
Wright State University, United States
Tanuja Tummala
Harrisburg University of Science and Technology, United StatesSubmit your abstract Today
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico